PUBLICATION: 
Breast Cancer Res Treat (2017) 166: 593. https://doi.org/10.1007/s10549-017-4428-9.
AUTHORS:
Laura J. van โt Veer, Christina Yau, Nancy Y. Yu, Christopher C. Benz, Bo Nordenskjรถld, Tommy Fornander, Olle Stรฅl, Laura J. Esserman, Linda Sofie Lindstrรถm
SUMMARY:
20yr BCSS and 10yr DMFS analysis of MammaPrint High Risk vs Low Risk patients in the STO trial.
Read more: van’t Veer et al_2017_Breast Cancer Research and Treatment_Tamoxifen Therapy Benefit…
Contact
For the US, Puerto Rico, Canada
and South America
Agendia Inc. USA, 22 Morgan, Irvine, CA 92618
(888) 321-2732
customercare@agendia.com
For outside the Americas
Agendia NV, Radarweg 60, 1043 NT Amsterdam, The Netherlands
+31 (0)20 462 1510
customerservice@agendia.com
ยฉ2024 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc.
CHIEF COMPLIANCE OFFICER
Stephanie has worked in compliance since 2005 and has extensive experience developing and managing programs to support compliance with global, federal, and state laws and regulations in the healthcare and biotech industries. Prior to joining Agendia, Stephanie spent a significant portion of her career serving as a compliance officer in laboratories, such as HealthTrackRx, NeoGenomics, and Myriad Genetics, and held compliance leadership roles in medical device, pharma, and large health systems.
Stephanie graduated Summa Cum Laude with a B.S. in Healthcare Administration from Northern Illinois University and is Certified in Healthcare Compliance (CHC), Data Privacy (CHP), Research Compliance (CHRC), and is a Certified Internal Auditor (CIA).
